Protagenic Therapeutics, Inc.\new annual cash and equivalents
2014
2015
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Protagenic Therapeutics, Inc.\new Cash & Equivalents Growth & History (PTIX)
Protagenic Therapeutics, Inc.\new's cash and equivalents was $1.5M for fiscal 2026.
View full Protagenic Therapeutics, Inc.\new company overviewProtagenic Therapeutics, Inc.\new annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $1.5M | $1.5M | +10285.92% |
| 2025 | 2025-03-31 | $14,531 | — | — |
| 2024 | 2024-12-31 | $79,568 | −$1.2M | −93.82% |
| 2023 | 2023-12-31 | $1.3M | $1.1M | +498.49% |
| 2022 | 2022-12-31 | $215,189 | −$325,982 | −60.24% |
| 2021 | 2021-12-31 | $541,171 | −$129,920 | −19.36% |
| 2020 | 2020-12-31 | $671,091 | −$127,532 | −15.97% |
| 2019 | 2019-12-31 | $798,623 | $436,137 | +120.32% |
| 2018 | 2018-12-31 | $362,486 | −$37,201 | −9.31% |
| 2017 | 2017-12-31 | $399,687 | −$2.7M | −87.11% |
| 2016 | 2016-12-31 | $3.1M | $3.1M | +92642.99% |
| 2015 · Dec 31 | 2015-12-31 | $3,343 | — | — |
| 2015 · Jun 30 | 2015-06-30 | $5,339 | −$95,661 | −94.71% |
| 2014 | 2014-06-30 | $101,000 | — | — |
Protagenic Therapeutics, Inc.\new quarterly cash and equivalents
As of Jun 30, 2011
As of Sep 30, 2011
As of Jun 30, 2013
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | $565,985 | −$3.5M | −86.18% |
| Q4 2026 | 2026-03-31 | $1.5M | $1.5M | +10285.92% |
| Q3 2026 | 2025-12-31 | $2.2M | $2.1M | +2680.82% |
| Q2 2026 | 2025-09-30 | $2.7M | $2.7M | +3713.17% |
| Q1 2026 | 2025-06-30 | $4.1M | $3.4M | +474.00% |
| Q4 2025 | 2025-03-31 | $14,531 | $12,906 | +794.22% |
| Q4 2024 | 2024-12-31 | $79,568 | −$1.2M | −93.82% |
| Q3 2024 | 2024-09-30 | $71,396 | −$81,936 | −53.44% |
| Q2 2024 | 2024-06-30 | $713,627 | $494,192 | +225.21% |
| Q1 2024 | 2024-03-31 | $1,625 | −$136,866 | −98.83% |
| Q4 2023 | 2023-12-31 | $1.3M | $1.1M | +498.49% |
| Q3 2023 | 2023-09-30 | $153,332 | −$4,991 | −3.15% |
| Q2 2023 | 2023-06-30 | $219,435 | −$119,231 | −35.21% |
| Q1 2023 | 2023-03-31 | $138,491 | −$343,684 | −71.28% |
| Q4 2022 | 2022-12-31 | $215,189 | −$325,982 | −60.24% |
| Q3 2022 | 2022-09-30 | $158,323 | −$301,792 | −65.59% |
| Q2 2022 | 2022-06-30 | $338,666 | −$11.6M | −97.16% |
| Q1 2022 | 2022-03-31 | $482,175 | $290,501 | +151.56% |
| Q4 2021 | 2021-12-31 | $541,171 | −$129,920 | −19.36% |
| Q3 2021 | 2021-09-30 | $460,115 | −$528,459 | −53.46% |
| Q2 2021 | 2021-06-30 | $11.9M | $10.8M | +910.16% |
| Q1 2021 | 2021-03-31 | $191,674 | −$562,298 | −74.58% |
| Q4 2020 | 2020-12-31 | $671,091 | −$127,532 | −15.97% |
| Q3 2020 | 2020-09-30 | $988,574 | $711,188 | +256.39% |
| Q2 2020 | 2020-06-30 | $1.2M | $841,752 | +247.91% |
| Q1 2020 | 2020-03-31 | $753,972 | $334,638 | +79.80% |
| Q4 2019 | 2019-12-31 | $798,623 | $436,137 | +120.32% |
| Q3 2019 | 2019-09-30 | $277,386 | −$154,546 | −35.78% |
| Q2 2019 | 2019-06-30 | $339,544 | $103,531 | +43.87% |
| Q1 2019 | 2019-03-31 | $419,334 | $76,047 | +22.15% |
| Q4 2018 | 2018-12-31 | $362,486 | −$37,201 | −9.31% |
| Q3 2018 | 2018-09-30 | $431,932 | −$520,202 | −54.64% |
| Q2 2018 | 2018-06-30 | $236,013 | −$391,812 | −62.41% |
| Q1 2018 | 2018-03-31 | $343,287 | −$2.4M | −87.49% |
| Q4 2017 | 2017-12-31 | $399,687 | −$2.7M | −87.11% |
| Q3 2017 | 2017-09-30 | $952,134 | −$2.5M | −72.71% |
| Q2 2017 | 2017-06-30 | $627,825 | −$3.2M | −83.43% |
| Q1 2017 | 2017-03-31 | $2.7M | −$1.0M | −26.82% |
| Q4 2016 | 2016-12-31 | $3.1M | $3.1M | +92642.99% |
| Q3 2016 | 2016-09-30 | $3.5M | $3.4M | +5828.59% |
| Q2 2016 | 2016-06-30 | $3.8M | $3.8M | +70853.16% |
| Q1 2016 · Mar 31 | 2016-03-31 | $3.8M | $3.7M | +464103.84% |
| Q4 2015 · Dec 31 | 2015-12-31 | $3,343 | −$146,657 | −97.77% |
| Q1 2016 · Sep 30 | 2015-09-30 | $58,850 | −$52,150 | −46.98% |
| Q4 2015 · Jun 30 | 2015-06-30 | $5,339 | −$95,661 | −94.71% |
| Q3 2015 | 2015-03-31 | $808 | — | — |
| Q2 2015 | 2014-12-31 | $150,000 | — | — |
| Q1 2015 | 2014-09-30 | $111,000 | — | — |
| Q4 2014 | 2014-06-30 | $101,000 | −$616,000 | −85.91% |
| As of Jun 30, 2013 | 2013-06-30 | $717,000 | — | — |
| As of Sep 30, 2011 | 2011-09-30 | $2.0M | — | — |
| As of Jun 30, 2011 | 2011-06-30 | $2.3M | — | — |
Protagenic Therapeutics, Inc.\new cash and equivalents trends
Between the periods ended 2014-06-30 and 2026-03-31, Protagenic Therapeutics, Inc.\new's cash and equivalents increased from $101,000 to $1.5M, a change of $1.4M. The latest reported quarter, Q1 2027, shows $565,985.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protagenic Therapeutics, Inc.\new source filings ↗